Partnerships & Alliances
Filter News
Found 54,022 articles
-
Boston-based Covant Therapeutics gained $10 million upfront in a deal with Boehringer Ingelheim to chase after a cancer immunotherapy target, ADAR1.
-
Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets
3/29/2023
Aquestive Therapeutics, Inc. today announced it has expanded its exclusive license and supply agreement with Atnahs Pharma UK Limited.
-
Thermo Fisher Scientific and Arsenal Biosciences Collaborate to Support Clinical Manufacturing of Autologous T-Cell Therapies
3/29/2023
Thermo Fisher Scientific today announced an update to our strategic collaboration to further the development of manufacturing processes for new cancer treatments.
-
Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101, a Phase 2/3-ready small molecule, to treat ophthalmic indications with high unmet medical need
3/29/2023
Théa Open Innovation (“TOI”), a sister company of ophthalmic specialty pharmaceutical company Laboratoires Théa, and Galimedix Therapeutics, Inc. (“Galimedix”), a clinical-stage biotechnology company addressing the cause of neurodegenerative diseases of the eye and central nervous system, announced today that they have signed a licensing agreement.
-
SamaCare Partners with AmerisourceBergen to Offer Prior Authorization Platform to Specialty Practices
3/29/2023
SamaCare today announced a partnership with AmerisourceBergen Specialty GPOs to offer specialty physician practices across oncology, retina, rheumatology, and neurology access to SamaCare's platform.
-
Cynerio and Sodexo Announce Partnership to Get Ahead of Risks and Attacks on Network-Connected Medical Devices
3/29/2023
Cynerio today announced a new partnership with Sodexo to provide hospitals and healthcare systems with unparalleled visibility into their IoMT footprint that allows for the immediate remediation of identified threats through step-by-step mitigation recommendations for each attack and risk.
-
Scivita Medical enters into Strategic Agreement with Boston Scientific in China
3/29/2023
Medical technology company Scivita Medical Technology Co., Ltd. ('Scivita Medical') and Boston Scientific (NYSE: BSX), one of the leading medical technology companies worldwide, have officially signed a Strategic Agreement for Scivita's Single-Use Percutaneous Choledochoscope.
-
Junshi Biosciences Announces Establishment of Joint Venture with Rxilient Biotech to Jointly Develop and Commercialize Toripalimab in Southeast Asia
3/29/2023
Shanghai Junshi Biosciences Co., Ltd and Rxilient Biotech announced the collaboration on the development and commercialization of the anti-PD-1 monoclonal antibody drug, toripalimab through joint venture in 9 Southeast Asian nations, including Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, and Vietnam.
-
Bicycle Therapeutics and Novartis announced Tuesday they have inked a deal worth up to $1.7 billion to discover and develop targeted radioligand therapies in oncology.
-
Bristol Myers Squibb is expanding its strategic collaboration with German partner Evotec for eight more years to discover and develop treatments for neurodegenerative diseases.
-
Freenome Adds Renown Health as Partner for the Sanderson Study
3/28/2023
Freenome, a privately held biotech company announced that Renown Health has joined as a partner for the Sanderson Study, Freenome's study of its multiomics platform, in combination with real-world data to detect multiple cancers.
-
Simulations Plus Enters New Strategic Collaboration to Discover Anticancer Therapies Through Its AI-Driven Drug Design Technology
3/28/2023
Simulations Plus, Inc. today announced that it established a strategic research collaboration with the Sino-American Cancer Foundation (SACF).
-
HMNC Brain Health and Develco Pharma Announce Last Patient Being Randomized in Oral Prolonged-Release Ketamine (KET01) Trial for Treatment-Resistant DepressionKET01 Phase 2 Clinical Trial with Topline Results Expected Mid-Year
3/28/2023
HMNC Brain Health together with Develco Pharma, announced that the last patient has been randomized in its proof-of-concept Phase II clinical trial of ‘Ketabon’, an oral prolonged-release ketamine formulation for Treatment-Resistant Depression.
-
Astellas and Roche Diabetes Care Japan ink partnership agreement to develop and commercialize integrated diabetes self-management solution with BlueStar®
3/28/2023
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced that it has entered into an agreement ("the Agreement") with Roche Diabetes Care Japan Co., Ltd. (Country Manager: Noriko Hattori, "Roche Diabetes Care Japan") for the development and commercialization of Roche Diabetes Care's world-renowned Accu-Chek® Guide Me blood glucose monitoring system with advanced accuracy as a combined medical product with BlueStar.
-
Factorial Biotechnologies collaborates with Watchmaker Genomics to dramatically simplify single-cell sequencing
3/28/2023
Factorial Biotechnologies has announced a collaboration with Watchmaker Genomics, a life sciences company that specializes in developing high-stringency applications for reading, writing, and editing of DNA and RNA.
-
Mission Bio Joins NSF Cell Manufacturing Research Initiative to Advance Cell Therapy Development
3/28/2023
Mission Bio has joined the National Science Foundation (NSF) Engineering Research Center for Cell Manufacturing Technologies (CMaT), leveraging its Tapestri® Platform to improve analytical assays and cell manufacturing processes.
-
ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement with UCSF for Innovative Intra-Cerebral Cellular Delivery Platform
3/28/2023
ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”) today announced an exclusive multi-year licensing agreement of intellectual property from UC San Francisco (UCSF) through its Innovation Ventures group to develop and commercialize a radially branching cellular delivery device for use both in the Operating Room under fluoroscopy/CT guidance and under MRI guidance.
-
Medline and MMCAP Infuse enter into national cooperative agreement
3/28/2023
Medline today announced a distribution agreement with the national cooperative purchasing organization MMCAP Infuse to enhance supply chain operations for government facilities providing healthcare services throughout the country.
-
Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
3/28/2023
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sonoma Biotherapeutics, Inc. today announced a collaboration to apply their scientific and clinical expertise and respective technology platforms to the discovery, development and commercialization of novel regulatory T cell (T reg ) therapies for autoimmune diseases.
-
Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases
3/28/2023
Sonoma Biotherapeutics, Inc. and Regeneron Pharmaceuticals, Inc. today announced a collaboration to apply their scientific and clinical expertise and respective technology platforms to the discovery, development and commercialization of novel regulatory T cell (Treg) therapies for autoimmune diseases.